Earnings summaries and quarterly performance for Co-Diagnostics.
Executive leadership at Co-Diagnostics.
Board of directors at Co-Diagnostics.
Research analysts who have asked questions during Co-Diagnostics earnings calls.
Recent press releases and 8-K filings for CODX.
Co-Diagnostics Addresses Tuberculosis Test Adoption and Explores Strategic Transaction
CODX
Product Launch
New Projects/Investments
M&A
- Co-Diagnostics' Executive Vice President of Business Development, Joseph Featherstone, addressed The Union 2025 World Conference on Lung Health regarding the adoption and implementation of a tuberculosis molecular diagnostic test.
- The company announced the development of a proprietary sample preparation instrument for point-of-care testing, designed for its upcoming Co-Dx™ PCR Mycobacterium Tuberculosis (MTB) Test Kit.
- Clinical performance testing for this new MTB test is planned to begin soon, with anticipated introduction to the Indian and South African markets.
- Co-Dx is exploring a strategic transaction for its Indian joint venture, CoSara Diagnostics Pvt. Ltd., which may include a merger with a SPAC.
Nov 20, 2025, 2:00 PM
Co-Diagnostics Initiates Clinical Evaluations for Respiratory Multiplex PCR Test
CODX
Product Launch
New Projects/Investments
- Co-Diagnostics, Inc. has initiated clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit.
- These evaluations are a critical step towards submitting for 510(k) clearance from the FDA for the upper respiratory multiplex point-of-care test and the Co-Dx PCR Pro™ instrument.
- The company is targeting the respiratory infectious disease diagnostics market, which was valued at $54.58 billion in 2024 and is projected to grow to $73.56 billion by 2030.
- The Co-Dx PCR platform, including the test kit and instrument, is not yet available for sale as it is subject to regulatory review.
Nov 18, 2025, 2:00 PM
Co-Diagnostics Reports Q3 2025 Results and Advances Strategic Initiatives
CODX
Earnings
New Projects/Investments
Product Launch
- Co-Diagnostics reported Q3 2025 revenue of $0.1 million, down from $0.6 million in Q3 2024, while significantly reducing its net loss to $5.9 million (or $0.16 per fully diluted share) compared to a $9.7 million loss in the prior year.
- The company is actively pursuing a potential SPAC transaction for its Indian joint venture, Cosera Diagnostics, to unlock value and secure long-term funding, and recently raised $10.8 million through direct offerings.
- Strategic international expansion includes the formation of the Comera joint venture with Arabian Eagle Manufacturing to localize its CODEX PCR platform across Saudi Arabia and 18 additional MENA nations.
- Co-Diagnostics is advancing its product pipeline, initiating clinical evaluations for its upper respiratory multiplex test (Flu A, B, COVID-19, RSV) and expects to initiate evaluations for its CODEX PCR MTB and HPV tests before year-end.
Nov 13, 2025, 9:30 PM
Co-Diagnostics Reports Q3 2025 Financial Results and Strategic Developments
CODX
Earnings
New Projects/Investments
- Co-Diagnostics, Inc. (CODX) reported a net loss of $5.9 million, or $0.16 per fully diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $9.7 million, or $0.32 per fully diluted share, in Q3 2024.
- Revenue decreased to $0.1 million in Q3 2025, down from $0.6 million in Q3 2024, primarily due to a reduction in grant revenue.
- As of September 30, 2025, the company held $11.4 million in cash, cash equivalents, and marketable securities.
- The company completed a Registered Direct Offering (RDO) with gross proceeds of approximately $3.8 million in Q3 2025, and another RDO subsequent to quarter end with gross proceeds of approximately $7.0 million.
- Strategic developments include signing a definitive agreement for the CoMira Diagnostics joint venture in KSA and 18 MENA nations, forming a new artificial intelligence (AI) business unit, and engaging Maxim Group LLC to pursue a strategic transaction for its India joint venture, CoSara Diagnostics.
Nov 13, 2025, 9:03 PM
Co-Diagnostics Reports Third Quarter 2025 Financial Results
CODX
Earnings
New Projects/Investments
- Co-Diagnostics reported revenue of $0.1 million for the third quarter ended September 30, 2025, a decrease compared to $0.6 million in Q3 2024, and a net loss of $5.9 million, or $0.16 per fully diluted share.
- As of September 30, 2025, the company held $11.4 million in cash, cash equivalents, and marketable securities.
- Subsequent to the quarter end, Co-Diagnostics closed a Registered Direct Offering with gross proceeds of approximately $7.0 million and signed a definitive agreement for a joint venture, CoMira Diagnostics, to commercialize its technologies in KSA and 18 MENA nations.
- The company also announced the formation of a new artificial intelligence (AI) business unit and engaged Maxim Group LLC to pursue a strategic transaction, which may include a SPAC transaction, for its India joint venture, CoSara Diagnostics.
Nov 13, 2025, 9:01 PM
Co-Diagnostics Forms Joint Venture in Saudi Arabia
CODX
New Projects/Investments
M&A
- Co-Diagnostics, Inc. (CODX) announced the formation of CoMira Diagnostics, a joint venture (JV) in the Kingdom of Saudi Arabia (KSA).
- This JV was recognized by Utah Governor Spencer Cox and BioUtah President and CEO Kelvyn Cullimore, underscoring Co-Diagnostics' expansion across the Middle East and North Africa.
- Co-Diagnostics is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostics technologies, including its proprietary Co-Dx PCR at-home and point-of-care platform.
Nov 12, 2025, 2:00 PM
CoDiagnostics Announces Saudi Arabia JV, AI Initiatives, and Plans for Cosara India SPAC
CODX
New Projects/Investments
Product Launch
- CoDiagnostics announced a joint venture in Saudi Arabia last week and new artificial intelligence initiatives this past Monday.
- The company plans to begin clinical trials for its ABCR test (Flu A, Flu B, COVID-19, RSV) in the US this month (November 2025), with HPV and TB clinical trials to follow in India and Africa.
- CoDiagnostics is pursuing a SPAC transaction for its Cosara joint venture in India to provide capitalization and additional value to stakeholders.
- The company's diagnostic device is significantly more affordable, costing $300 to $500 at scale compared to $10,000-$20,000 for standard PCR devices, and its consumable cartridges offer 70% to 80% margins.
Nov 5, 2025, 4:00 PM
Co-Diagnostics Engages Maxim Group to Explore SPAC Transaction for CoSara Diagnostics
CODX
M&A
New Projects/Investments
- Co-Diagnostics, Inc. has engaged Maxim Group LLC as its exclusive financial advisor.
- The engagement aims to identify strategic alternatives for the Company's Indian joint venture, CoSara Diagnostics Pvt. Ltd..
- Potential alternatives include a merger with a Special Purpose Acquisition Company (SPAC) or similar entity listed on a U.S. national securities exchange.
- The objective is to unlock value for CoSara and Co-Diagnostics' shareholders.
Nov 5, 2025, 2:00 PM
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering
CODX
- Co-Diagnostics, Inc. announced the pricing of a registered direct offering to raise approximately $7.0 million in gross proceeds.
- The offering involves the sale of 12,727,272 shares of common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.55 per share.
- The company intends to use the proceeds from the offering for working capital and general corporate purposes.
- The offering is expected to close on or about October 29, 2025.
Oct 29, 2025, 9:05 PM
Co-Diagnostics Announces Closing of $7.0 Million Stock Offering
CODX
New Projects/Investments
- Co-Diagnostics, Inc. (CODX) announced the closing of its previously announced offering on October 29, 2025.
- The offering involved 12,727,272 shares of common stock (or pre-funded warrants) at an offering price of $0.55 per share.
- The company received approximately $7.0 million in gross proceeds from the offering.
- Proceeds from the offering are intended for working capital and general corporate purposes.
Oct 29, 2025, 4:51 PM
Quarterly earnings call transcripts for Co-Diagnostics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more